190 related articles for article (PubMed ID: 32806028)
1. Boosting Natural Killer Cell-Based Cancer Immunotherapy with Selenocystine/Transforming Growth Factor-Beta Inhibitor-Encapsulated Nanoemulsion.
Liu C; Lai H; Chen T
ACS Nano; 2020 Sep; 14(9):11067-11082. PubMed ID: 32806028
[TBL] [Abstract][Full Text] [Related]
2. Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma.
Yvon ES; Burga R; Powell A; Cruz CR; Fernandes R; Barese C; Nguyen T; Abdel-Baki MS; Bollard CM
Cytotherapy; 2017 Mar; 19(3):408-418. PubMed ID: 28109751
[TBL] [Abstract][Full Text] [Related]
3. Selenium-containing ruthenium complex synergizes with natural killer cells to enhance immunotherapy against prostate cancer via activating TRAIL/FasL signaling.
Lai H; Zeng D; Liu C; Zhang Q; Wang X; Chen T
Biomaterials; 2019 Oct; 219():119377. PubMed ID: 31374478
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models.
Otegbeye F; Ojo E; Moreton S; Mackowski N; Lee DA; de Lima M; Wald DN
PLoS One; 2018; 13(1):e0191358. PubMed ID: 29342200
[TBL] [Abstract][Full Text] [Related]
5. Blocking transforming growth factor-β signaling pathway augments antitumor effect of adoptive NK-92 cell therapy.
Yang B; Liu H; Shi W; Wang Z; Sun S; Zhang G; Hu Y; Liu T; Jiao S
Int Immunopharmacol; 2013 Oct; 17(2):198-204. PubMed ID: 23806302
[TBL] [Abstract][Full Text] [Related]
6. Combined delivery of a TGF-β inhibitor and an adenoviral vector expressing interleukin-12 potentiates cancer immunotherapy.
Jiang J; Zhang Y; Peng K; Wang Q; Hong X; Li H; Fan G; Zhang Z; Gong T; Sun X
Acta Biomater; 2017 Oct; 61():114-123. PubMed ID: 28483693
[TBL] [Abstract][Full Text] [Related]
7. Nano-chemical priming strategy to enhance TGF-β resistance and anti-tumor activity of natural killer cells.
Choi SH; Cho HB; Choi JH; Kim HJ; Jang HJ; Cho S; Maeng E; Park H; Ryu KS; Park KH; Park KS
J Control Release; 2024 Mar; 367():768-778. PubMed ID: 38341178
[TBL] [Abstract][Full Text] [Related]
8. Comparable transforming growth factor beta-mediated immune suppression in ex vivo-expanded natural killer cells from cord blood and peripheral blood: implications for adoptive immunotherapy.
Chaudhry K; Dowlati E; Long MD; Geiger A; Lang H; Gomez EC; Muniraj N; Sanchez CE; Singh PK; Liu S; Bollard CM; Cruz CRY
Cytotherapy; 2022 Aug; 24(8):802-817. PubMed ID: 35589475
[TBL] [Abstract][Full Text] [Related]
9. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity.
Kopp HG; Placke T; Salih HR
Cancer Res; 2009 Oct; 69(19):7775-83. PubMed ID: 19738039
[TBL] [Abstract][Full Text] [Related]
10. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
11. Ruthenium complexes boost NK cell immunotherapy via sensitizing triple-negative breast cancer and shaping immuno-microenvironment.
Chen Q; He L; Li X; Xu L; Chen T
Biomaterials; 2022 Feb; 281():121371. PubMed ID: 35063740
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of NKG2DLs by TGF-β in human lung cancer cells.
Lee YS; Choi H; Cho HR; Son WC; Park YS; Kang CD; Bae J
BMC Immunol; 2021 Jul; 22(1):44. PubMed ID: 34253166
[TBL] [Abstract][Full Text] [Related]
13. Selenadiazole derivative-loaded metal azolate frameworks facilitate NK cell immunotherapy by sensitizing tumor cells and shaping immuno-suppressive microenvironments.
Yang Y; Jiang Y; Xie B; Shi S; Pi F; Chen M; Sang C; Xu L; Chen T
Biomater Sci; 2023 Feb; 11(4):1517-1529. PubMed ID: 36606484
[TBL] [Abstract][Full Text] [Related]
14. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
15. Enhanced NK cell adoptive antitumor effects against breast cancer in vitro via blockade of the transforming growth factor-β signaling pathway.
Zhao Y; Hu J; Li R; Song J; Kang Y; Liu S; Zhang D
Onco Targets Ther; 2015; 8():1553-9. PubMed ID: 26124672
[TBL] [Abstract][Full Text] [Related]
16. Impairment of NKG2D-Mediated Tumor Immunity by TGF-β.
Lazarova M; Steinle A
Front Immunol; 2019; 10():2689. PubMed ID: 31803194
[TBL] [Abstract][Full Text] [Related]
17. Platelet-derived TGF-β1 mediates the down-modulation of NKG2D expression and may be responsible for impaired natural killer (NK) cytotoxicity in women with endometriosis.
Guo SW; Du Y; Liu X
Hum Reprod; 2016 Jul; 31(7):1462-74. PubMed ID: 27130956
[TBL] [Abstract][Full Text] [Related]
18. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
19. The TGF-β-induced up-regulation of NKG2DLs requires AKT/GSK-3β-mediated stabilization of SP1.
Chen XH; Lu LL; Ke HP; Liu ZC; Wang HF; Wei W; Qi YF; Wang HS; Cai SH; Du J
J Cell Mol Med; 2017 May; 21(5):860-870. PubMed ID: 28165192
[TBL] [Abstract][Full Text] [Related]
20. MMP-2 Inhibitor-Mediated Tumor Microenvironment Regulation Using a Sequentially Released Bio-Nanosystem for Enhanced Cancer Photo-Immunotherapy.
Liu H; Lei D; Li J; Xin J; Zhang L; Fu L; Wang J; Zeng W; Yao C; Zhang Z; Wang S
ACS Appl Mater Interfaces; 2022 Sep; 14(37):41834-41850. PubMed ID: 36073504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
